PARP Inhibitor Market By Drug (Lynparza, Niraparib, Rucaparib and Others), By Indication (Ovarian cancer, Breast cancer, Prostate cancer, Lung cancer and Others), By Distribution Channel (Hospital pharmacies, Online pharmacies and Others), and By Region - Trends, Analysis and Forecast till 2034

Estimates for the PARP Inhibitor Market place it at a valuation of US$ 12.5 billion in 2024 and a compound annual growth rate (CAGR) of 18.3% to US$ 67.0 billion by 2034.

When cancer becomes more aggressive, it is more likely to spread to other body parts. The rise in severe cancer cases has made cancer treatment more difficult for the medical community to provide.  Many cancer treatment modalities, including radiation therapy, PARP inhibitors, chemotherapy, and surgery, are being used. Numerous heritable cancers are treated with PARP inhibitors. These inhibitors are a desirable target for cancer therapy because they rely on PARP cells rather than normal cells. Chemotherapy and radiation therapy aim to destroy cancer cells by causing significant damage to DNA. By impeding PARP1 DNA repair, these treatments may be more successful. Proteins called BRCA1, BRCA2, and PALB2 are crucial for the error-free homologous recombinational repair, or HRR, pathway, which repairs double-strand DNA breaks. One of these proteins' genes may become mutated, which may result in mistakes in DNA repair that ultimately lead to breast cancer. The mutated gene has the potential to kill cells when they sustain enough damage all at once. One protein that is crucial for fixing single-strand breaks is called PARP1.